$1.00
-0.03 (-2.91%)
Open$1.02
Previous Close$1.03
Day High$1.02
Day Low$1.00
52W High$3.68
52W Low$0.73
Volume—
Avg Volume8.1K
Market Cap12.09M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,331.0% upside
Current
$1.00
$1.00
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 65.9K | 1.99M | 1.82M |
| Net Income | -2,396,269 | -271,887 | -219,394 |
| Profit Margin | -3,621.2% | -13.7% | -12.0% |
| EBITDA | -2,095,224 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.05 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |